You are here
CML Therapy: Making History, Making Progress. LLS interviews Brian J. Druker MD. March 2008
Brian Druker's original research into developing a way of blocking the protein (BCR/ABL) that drives CML, culminated in the development of a Tyrosine Kinase Inhibitor... namely Glivec/imatinib.
.. namely Glivec/imatinib.
In June this year it will be 10 years since the start of the original trials for STI 571 (Glivec/imatinib).
It is an important anniversary for all those diagnosed with CML.